Trials / Recruiting
RecruitingNCT06302491
A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia
A Study of Safety and Efficiency of AND017 in Patients With Transfusion Dependent and Non-transfusion Dependent β-thalassemia
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- Sponsor
- Kind Pharmaceuticals LLC · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II, randomized, double-blinded, placebo-controlled study to treat patients with transfusion-dependent and non-transfusion dependent β -thalassemia with AND017 and optimal supportive care, including blood transfusion and iron removal, based on the clinician's judgment and practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AND017 capsules | Administer AND017 capsules once per day (QD) |
| DRUG | AND017 Placebo | Administer AND017 matching placebo capsules once per day (QD) |
Timeline
- Start date
- 2024-05-27
- Primary completion
- 2026-12-01
- Completion
- 2027-07-01
- First posted
- 2024-03-08
- Last updated
- 2026-02-27
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06302491. Inclusion in this directory is not an endorsement.